CHCT:NYE-Community Healthcare Trust Incorporated (USD)

COMMON STOCK | REIT-Healthcare Facilities | NYE

Last Closing Price

USD 48.02

Change

-0.60 (-1.23)%

Market Cap

USD 1.20B

Volume

0.18M

Avg Analyst Target

USD 52.00 (+8.29%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Community Healthcare Trust Incorporated is a real estate investment trust that focuses on owning income-producing real estate properties associated primarily with the delivery of outpatient healthcare services in our target sub-markets throughout the United States. The Company had investments of approximately $667.3 million in 131 real estate properties as of September 30, 2020, located in 33 states, totaling approximately 2.8 million square feet.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for REIT-Healthcare Facilities

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
WELL Welltower Inc

-2.44 (-2.85%)

USD36.10B 61.60 35.76
VTR Ventas Inc

-1.10 (-1.95%)

USD22.22B 138.77 19.54
MPW Medical Properties Trust Inc

-0.26 (-1.24%)

USD12.50B 22.63 17.37
OHI Omega Healthcare Investors Inc

-0.63 (-2.00%)

USD7.52B 34.08 16.52
HTA Healthcare Trust of America In..

-0.64 (-2.09%)

USD6.63B 93.65 20.85
HR Healthcare Realty Trust Incorp..

-0.56 (-1.80%)

USD4.52B 114.54 21.18
DOC Physicians Realty Trust

-0.16 (-0.87%)

USD3.97B 58.65 19.40
NHI National Health Investors Inc

-1.13 (-1.98%)

USD2.62B 16.76 14.08
LTC LTC Properties Inc

-0.53 (-1.62%)

USD1.29B 23.51 14.88
GMRE Global Medical REIT Inc

-0.18 (-1.20%)

USD0.97B 161.88 24.66

ETFs Containing CHCT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (REIT-Healthcare Facilities)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.93% 57% F 34% F
Dividend Return 2.74% 14% F 59% F
Total Return 4.67% 57% F 35% F
Trailing 12 Months  
Capital Gain 5.91% 64% D 25% F
Dividend Return 3.78% 7% F 55% F
Total Return 9.69% 50% F 25% F
Trailing 5 Years  
Capital Gain 109.51% 100% A+ 82% B-
Dividend Return 35.66% 83% B 90% A-
Total Return 145.17% 100% A+ 86% B
Average Annual (5 Year Horizon)  
Capital Gain 20.37% 100% A+ 81% B-
Dividend Return 5.33% 64% D 86% B
Total Return 25.69% 100% A+ 85% B
Risk Return Profile  
Volatility (Standard Deviation) 19.07% 57% F 60% D-
Risk Adjusted Return 134.73% 100% A+ 97% A+
Market Capitalization 1.20B 36% F 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(REIT-Healthcare Facilities)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 56.67 57% F 13% F
Price/Book Ratio 2.60 15% F 38% F
Price / Cash Flow Ratio 24.83 21% F 17% F
EV/EBITDA 24.33 23% F 20% F
Management Effectiveness  
Return on Equity 5.09% 43% F 37% F
Return on Invested Capital 4.66% 64% D 53% F
Return on Assets 2.81% 57% F 53% F
Debt to Equity Ratio 49.40% 71% C- 63% D
Technical Ratios  
Short Ratio 4.36 77% C+ 28% F
Short Percent 1.34% 92% A- 72% C-
Beta 0.47 100% A+ 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.